News

Newsletter

28 de October de 2014

Newsletter 2014.07 – ANVISA publishes resolutions on new procedures relative to marketing authorization in Brazil: RDC #58 and #60/2014

The main law regulating the health system in Brazil – Law #6,360 dated 1976 – establishes that each and every drug available in the pharmaceutical market must be approved by the Ministry of Health. Since the creation of the Brazilian FDA (called ANVISA), this autonomous autarchy subordinated to the Ministry of Health is in charge of issuing marketing authorization for drugs for human use and of establishing specific resolutions in order to regulate each of the existing categories of medicaments, such as the new drugs, generics, similars, biologicals.

According to ANVISA’s requirements, the documentation submitted by the manufacturers of both generic and similar drugs, upon applying for marketing approval, is significantly simplified compared to the reference product (the so-called “abridged process”), as only pharmaceutical equivalence and relative bioavailability/ bioequivalence assays are required to obtain approval for products pertaining to these categories.

It should be noted that, since the publication of Resolutions RDC #133 (new applications for marketing approval) and RDC #134 (similars, already approved), both dated May 29, 2003, ANVISA has begun to require proof of therapeutic equivalence also for similar drugs; therefore, it is estimated that all manufacturers of these products will have complied with such requirement by the end of 2014.

Accordingly, studies of pharmaceutical equivalence and bioavailability/bioequivalence became necessary in order to obtain marketing authorization for both generic and similar drugs, although the latter were not then yet considered to be interchangeable with the reference product.

Back

Last related news

20 de October de 2025

Brazil enacts the ECA Digital: a landmark law for children’s rights in the Digital Age

Last month, Brazil took a major step toward regulating the digital environment for children and adolescents with the enactment of the ECA Brazil enacts the ECA Digital: a landmark law for children’s rights in the Digital Age

Ler notícia

17 de October de 2025

New Rules for Clinical Research: Federal Government Bets on Regulation to Boost Innovation and Investment

Brazil, despite being among the top 20 countries in terms of the number of clinical trials, contributes less than 2% of global New Rules for Clinical Research: Federal Government Bets on Regulation to Boost Innovation and Investment

  • Kasznar Leonardos
  • Ler notícia

    13 de October de 2025

    2025 Nobel Prize in Economics: innovation as an engine of transformation

    The 2025 Nobel Prize in Economic Sciences recognized Joel Mokyr, Philippe Aghion, and Peter Howitt for their theoretical contributions on how innovation 2025 Nobel Prize in Economics: innovation as an engine of transformation

    Ler notícia